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Nucleic acid base sequence of proteins plays a crucial role in the expression of gene. The gene is 
responsible for the synthesis of proteins and these proteins, which are synthesized, are responsible for 
the biological process and also for dreadful diseases as well. Once if the nucleic acid sequence is 
altered, we would be able to block or transfer the message for protein synthesis, there by preventing 
the particular protein, which is responsible for the disease.  These nucleic acids act as drugs by 
different mechanisms, they may bind with the synthesized proteins, and they can hybridize to a 
messenger RNA leading to translation arrest or may induce degradation to target RNA. In this way the 
nucleic acids act as drug for inhibiting gene expression or protein synthesis. This article examines 
about the different types of nucleic acid drugs, their mechanisms, advantages, drawbacks and their 
future prospects.  
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INTRODUCTION         
 
The discovery of that genetic information is coded along 
the length of a polymeric molecule composed of only 4 
types of monomeric units is one of the major scientific 
achievements of this century. This polymeric molecule 
DNA is chemical basis of heredity and is organized into 
genes, the fundamental units of genetic information. Genes 
control the synthesis of various types of RNA most of 
which are involved in protein synthesis (Daryl, 1993) 
The main function of a gene is to encode a message that 
can be transferred and expressed in order that protein may 
be synthesized. Three over all processes are involved in 








*Corresponding author. E-mail: ejeru@rediffmail.com, 
ejeru@hotmail.com; Tel- 07422 255734; Fax no- 07422 
255504. 
replicated Secondly a specific base sequence (a gene) 
must be transcribed from DNA to form a messenger RNA 
(mRNA) molecule having a complementary base 
sequence. Finally translation of the message by transfer 
RNA (tRNA) at the ribosome is executed to assemble a 
protein. Modulation of specific gene expression and noting 
concomitant changes in cell physiology and function can 
provide critical insight into the biological functions of 
particular genes. Specific modulation of gene expression 
may also be beneficial in inflammatory, neoplastic or viral 
diseases since it would be desirable to effect only the 
inflammatory genes, oncogenes or viral genes without 
harming the normal functions of the cell.  
The majority of currently employed pharmacological 
approaches for modulation of gene function rely upon the 
interaction of low molecular weight chemical compounds 
with proteins targets so as to alter the function of the 
protein. Those chemical compounds are nucleic acids 
(Vyas and Dixit, 2002). 
Nucleic acids may be defined as the macromolecules in 
which the nucleotides remain linked to each other by 






TYPES OF NUCLEIC ACID DRUGS 
 
Nucleic acids are responsible for the direction of 
metabolism throughout the life of a cell. They direct the 
synthesis of proteins, control the synthesis of enzymes, 
and are responsible for the transfer of genetic information 
from one offspring to another. For the clinician, they are 
major interest as they are undoubtedly involved in the 
causation of cancers and other diseases. These nucleic 
acid drugs can be subdivided in to five classes based upon 
their target site and mechanism of action. These are 
Aptamers, Antisense oligonucleotides, Ribozyme nucleic 





Aptamers from the latin aptus (meaning to fit) are single 
stranded or double stranded nucleic acids. These are 
selected and amplified oligonucleotides that have been 
isolated from random pools of synthetic oligonucleotides 
according to their ability to bind with high affinity to 
biological target molecules (Ellington and Szostak, 1990). 
Aptamers as therapeutics would most likely bind proteins 
involved in the regulation and expression of genes 
dependent upon activity of protein.  
The production of aptamers involves synthesis of random 
pools of oligonucleotides containing approximately 10 
different molecular species, each having a different 
nucleotide sequence (Riordan et al., 1991). These pools 
are then incubated with target molecules and substances 
that bind with the highest affinity are isolated by physical or 
filter binding. The next step involves amplification of the 
isolated pool by enzymatic procedures, and then binding 
selection and amplification cycles are repeated until the 
pool is enriched with only those oligonucleotides that have 
the greatest affinity. This technique allows for the selection 
of oligonucleotides that by chance, have the correct three-
dimensional structure to bind to the target molecule. In 
subsequent steps, the high affinity oligonucleotides are 
evaluated for their ability to inhibit the activity (for example, 
enzymatic activity) of the target to which they bind. 
 
 
Aptamers as therapeutic and diagnostic agents 
 
Using this method, many powerful antagonists of such 
proteins have been found. In order for these antagonists to 
work in animal models of disease and in humans, it is 
necessary to modify the aptamers. First of all, sugar 
modifications of nucleoside triphosphates are necessary to 
render the resulting aptamers resistant to nucleases found 
in serum. Changing the 2'OH groups of ribose to 2'F or 
2'NH2 groups yields aptamers, which are long lived in 
blood. The relatively low molecular weight of aptamers 
(8000-12000) leads to rapid clearance from the blood.  




Aptamers can be kept in the circulation from hours to 
days by conjugating them to higher molecular weight 
vehicles. When modified, conjugated aptamers are injected 
into animals, they inhibit physiological functions known to 
be associated with their target proteins. A new approach to 
diagnostics is also described. The use of photo-cross-
linkable aptamers will allow the covalent attachment of 
aptamers to their cognate proteins, with very low 
backgrounds from other proteins in body fluids. Finally, 
protein staining with any reagent, which distinguishes 
functional groups of amino acids from those of nucleic 
acids (and the solid support), will give a direct readout of 
proteins on the solid support. 
Only a few instances of oligonucleotide aptamers 
displaying biological effects have been reported. Double 
stranded aptamer which acts on B cells, phosphorothiote 
which acts on T cells, phosphodiester aptamers which acts 
on thrombin for anticoagulation are few examples of 
aptamers (Riordan et al., 1991; Ess et al., 1994). 
 
 
Advantages when compared to antibodies 
 
Aptamers can be isolated by a simple in vitro process for 
virtually any target, even if it is toxic or has low 
immunogenicity. They are specific drug-like antagonists of 
protein function. Being specific interaction partners, they 
can be integrated into almost any target validation and 
drug screening program. Aptamers tend to bind grooves 
and clefts on proteins and can recognize binding pockets in 
ways similar to that of small molecules. They can be 
chemically synthesized offering a wide variety of targeted 
modifications such as fluorescent reporters or affinity tags. 
They are also stable under various buffer conditions and 
resistant to harsh treatments such as physical or chemical 
denaturation with no loss off activity. 
 
 
ANTISENSE OLIGONUCLEOTIDES  
  
Zamecnik and Stephenson (1978) were the first to propose 
the use of synthetic oligonucleotides for the therapeutic 
purposes. Antisense therapy is designed to prevent or at 
least lower expression of a specific gene. An 
oligonucleotide that has a sequence that is complementary 
to the mRNA of the target gene is introduced into the cell. It 
will bind to the mRNA of the target gene and block 
translation of the message into protein. It may bind to DNA 
in the nucleus, blocking transcription or to the transcript 
during its processing and transport from the nucleus to the 
cytoplasm: all these interactions would reduce expression 
of gene. 
To inhibit translation, the antisense oligonucleotides must 
reach the interior of the cell unaltered. That ability depends 
upon stability of the oligonucleotide toward extra and 
intracellular enzymes, ability to penetrate  through  the  cell  




membrane and once if it has reached the cytoplasm it must 
bind specifically and with sufficient affinity to the target 
mRNA to inhibit its translation into the corresponding 
protein. In order to meet all these requirements it is 
necessary for normal oligonucleotides to be chemically 
modified in a suitable manner. A minimum length for 
antisense oligonucleotides in order to get specific binding 
is 11 bases, but most being tested are in the 15-25 base 
range. The most commonly used antisense 
oligonucleotides (ASONs) are phosphorothioates and 
methyl phophonates. Methyl phosphonates are uncharged 
and therefore more lipophilic than native DNA or RNA and 
may penetrate the cells better. However, solubility may be 
a problem with methyl phosphonates and the doses of 
methyl phosphonates are high because they become 
bound to membranes and less of a dose is available to 
bind to mRNA. Therefore, phosphorothioates gained favor 
with several companies (Elbashir et al, 2001; Stein, 2001). 
One of the major challenges for antisense approaches is 
the stabilization of oligonucleotides, as unmodified 
oligodeoxynucleotides are rapidly degraded in body fluids 
by nucleases. A vast number of chemically modified 
nucleotides have been used in antisense experiments. 
According to their generations they have been categorized 
in to three types.  
 
 
First generation antisense-oligonucleotides 
 
Phosphorothioate (PS) oligodeoxynucleotides are the 
major representatives of first generation DNA analogs that 
are the best-known and most widely used ASONs. In this 
class of oligonucleotides, one of the nonbridging oxygen 
atoms in the phophodiester bond is replaced by sulfur. PS 
DNA oligonucleotides were first synthesized in the 1960s 
by Eckstein and colleagues (2000) and were first used as 
ASONs for the inhibition of HIV replication by Matsukura 
and coworkers (1987).  
The introduction of phosphorothioate linkages into 
oligonucleotides was primarily intended to enhance their 
nuclease resistance. PS DNAs have a half-life in human 
serum of approximately 9–10 h compared to 1 h for 
unmodified oligodeoxynucleotides (Phillips and Zhang, 
2000). In addition to nuclease resistance, PS DNAs form 
regular Watson–Crick base pairs, activate RNase H, carry 
negative charges for cell delivery and display attractive 
pharmacokinetic properties.  
The major disadvantage of PS oligodeoxynucleotides is 
their binding to certain proteins, particularly those that 
interact with polyanions such as heparin-binding proteins. 
The reason for this nonspecific interaction is not yet fully 
understood, but it may cause cellular toxicity (Brown et al., 
1994; Levin, 1999).  
 
 
Second generation antisense-oligonucleotides 
 
The  problems  associated with phosphorothioate  oligo     





second generation oligonucleotides containing nucleotides 
with alkyl modifications at the 2' position of the ribose. 2'-O-
methyl and 2'-O-methoxy-ethyl RNA are the most important 
members of this class. ASONs made of these building 
blocks are less toxic than phosphorothioate DNAs and 
have a slightly enhanced affinity towards their 
complementary RNAs. Questions regarding its efficiency to 
induce RNase H cleavage of the target RNA are the matter 
to concern regarding this second generation 
oligonucleotides (Crooke et al., 1995).  
 
 
Third generation antisense-oligonucleotides 
 
In recent years a variety of modified nucleotides have been 
developed to improve properties such as target affinity, 
nuclease resistance and pharmacokinetics. The concept of 
conformational restriction has been used widely to enhance 
binding affinity and biostability. In analogy to the previous 
terms ‘first generation’ for phosphorothioate DNA and 
‘second generation’ for 2'-O-alkyl-RNA, these novel 
nucleotides will subsequently be subsumed under the term 
‘third generation’ antisense agents. Few novel modified 
nucleotides, which have a great potential as antisense 
molecules are  peptide nucleic acids (PNAs), N3’ P5’ 
phosphoroamidates (NPs), 2-Deoxy-2’-fluoro-β-d-arabino 
nucleic acid (FANA), and locked nucleic acid (LNA) 
(Nielsen, 1999; Gryaznov and Chen, 1994; Damha et al., 





Catalytic RNAs, or ribozymes, are RNAs, which 
catalytically cleave covalent bonds in a target RNA. The 
catalytic site is the result of the conformation adopted by 
the RNA-RNA complex in the presence of divalent cations. 
In the early 1980s, Cech and coworkers discovered the 
self-splicing activity of the group I intron of Tetrahymena 
thermophilia (Cech, 1981) and coined the term ‘ribozymes’ 
to describe these RNA enzymes. Shortly thereafter, Altman 
and colleagues discovered the active role of the RNA 
component of RNase P in the process of tRNA maturation 
(Guerrier, 1983). This was the first characterization of a 
true RNA enzyme that catalyses the reaction of a free 
substrate, i.e. possesses catalytic activity in trans. A variety 
of ribozymes, catalyzing intramolecular splicing or cleavage 
reactions, have subsequently been found in lower 
eukaryotes, viruses and some bacteria.  
Although natural ribozymes can be divided into several 
broad classes based upon structure and mechanism, two 
structural classes are the basis for the design of most trans 
acting ribozymes. (i) Hammer head ribozymes are found in 
the self-cleaving domain of plus-strand satellite RNAs from  
tobacco ringspot virus and (ii) Hairpin ribozymes are found 





from tobacco ringspot virus. A hammerhead ribozyme was 
isolated from viroid RNA and its dissection into enzyme and 
substrate strands (Uhlenbeck, 1987; Haseloff and Gerlach, 
1988) transformed this cis-cleaving molecule into a target-
specific trans-cleaving enzyme with a great potential for 
applications in biological systems. This minimized 
hammerhead ribozyme is less than 40 nucleotides long and 
consists of two substrate binding arms and a catalytic 
domain.  
For the development of a therapeutic hammerhead 
ribozyme similar problems have to be solved as described 
for ASONs. Some steps, however, are more challenging 
due to the catalytic nature of ribozymes. Firstly, suitable 
target sites have to be identified, secondly the 
oligoribonucleotides have to be stabilized against 
nucleolytic degradation and thirdly the ribozymes have to 
be delivered into the target cells. Stabilization of ribozymes 
is even more difficult than protection of ASOns, as the 
introduction of modified nucleotides very often leads to 
conformational changes that abolish catalytic activity 





Only recently, research in the antisense field increased in 
impact by the discovery of RNA interference (RNAi). This 
naturally occurring phenomenon as a potent sequence-
specific mechanism for post-transcriptional gene silencing 
was first described for the nematode worm Caenorhabditis 
elegans (Fire et al., 1998). RNA interference is initiated by 
long double-stranded RNA molecules, which are processed 
into 21–23 nucleotides long RNAs by the Dicer enzyme. 
This RNase III protein is thought to act as a dimer that 
cleaves both strands of dsRNAs and leaves two-
nucleotide, 3' overhanging ends. These small interfering 
RNAs (siRNAs) are then incorporated into the RNA-
induced silencing complex (RISC), a protein·RNA complex, 
and guide a nuclease, which degrades the target RNA.  
The 21 nucleotide-long siRNA duplexes with 3' 
overhangs can specifically suppress gene expression in 
mammalian cells (Yu et al., 2002). So it is thought to 
provide a significantly higher potency compared to 
traditional antisense approaches. Not only short double-
stranded RNA molecules but also short hairpin RNAs 
(shRNAs), i.e. fold-back stem-loop structures that give rise 
to siRNA after intracellular processing, can induce RNA 
interference.  
An alternative approach to prolong siRNA-mediated 
inhibition of gene expression is the introduction of modified 
nucleotides into chemically synthesized RNA, despite the 
fact that even unmodified short double-stranded RNA 
revealed an unexpectedly high stability in cell culture and in 
vivo. For certain applications, however, further 
enhancement of the siRNA stability might be desirable 
(Amarzguioui et al., 2003).  




Taken together, first promising in vivo experiments with 
siRNA have already been performed and further 
therapeutically important genes are expected to be 
targeted soon. No toxic reactions after siRNA application 
have been observed in the studies performed to date, but 
great care has to be taken to rule out severe side-effects of 
long-term induction of RNAi before trials can be started to 
treat human diseases. Because silencing of gene 
expression by siRNAs is similar to traditional antisense 
technology, researchers will be able to benefit from the 
lessons learned for more than a decade such as the 
requirement to use proper controls to proof a specific 
knock-down of gene expression and a careful analysis of 




ANTIGENE NUCLEIC ACID COMPOUNDS 
 
Nucleic acids targeted to genomic DNA have been termed 
antigene nucleic acids. Antigene nucleic acids are 
designed to bind to single stranded or double stranded 
DNA. Binding of single stranded DNA may occur at a 
replication or transcription bubble, and thereby interfere 
with either of these processes, although gene specificity 
would be expected only when the antigene compound 
interferes with transcription processes. Alternatively the 
antigene compound may bind the major groove of double 
stranded DNA and form a triple helix or triplex. Triplex 
formation may then prevent the interaction of various 
protein factors required for transcription or it may physically 
block the initiation or elongation of the transcription 
complex. 
Each of the nucleic acid bases possesses hydrogen 
bond donor and acceptor groups, which enable it to 
engage specific interaction with various ligands. Parts of 
these groups are involved in hydrogen bonding interactions 
within Watson-Crick base pairs of double helical DNA. But 
several recognition sites still remain in both major and 
minor grooves. Crystal structures of nucleic acid 
components have revealed that nucleic acid bases 
themselves can use some of these hydrogen-bonding 
possibilities. For example thymine can form two hydrogen 
bonds with the N (7) and NH2 (6) groups of adenine and/or 
with the NH2 (6) and N (1) groups (Roy, 1993; Hanvey et 
al., 1992). 
A triplex of bases can be obtained where one adenine is 
hydrogen bonded to two thymines. Similarly, cytosine, 
once protonated, can bind to guanine in a Watson-Crick 
G.C. base pair. These base triplets are isomorphous. 
Consequently, a homopurine-homopyramidine sequence of 
duplex DNA could be recognized by a homopyrimidine 
oligonucleotide forming a local triple helix. Additionally, 
oligonucleotides containing G and T residues will form 
triplexes with DNA target sites. The orientation of the 
binding of the G and T triplex forming oligonucleotides is 
dependent upon the exact sequence of the target site. 






Though the nucleic acids play a vital role in preventing 
dreadful diseases, they must overcome several measures 
before they can be widely applied as therapeutics. 
Researchers are concern about the stability of 
polynucleotides in biological systems, optimizing the affinity 
and efficacy of the drug without reducing its selectivity, 
targeting and delivering across cell membranes. 
Since phosphodiester nucleic acids are extremely 
sensitive to nucleases in serum and cells, they undergo 
degradation. Chemical modification may affect the affinity 
or activity of the nucleic acid drugs. This can be overcome 
by introduction of hairpin forming sequence which stabilize 
the transcript towards exonucleases, provided the hairpain 
does not adversely affect the affinity of the drugs. 
Subcellular distribution of nucleic acid drugs is an 
important aspect of their activity.  Oligonucleotides, when 
directly introduced into the cytoplasm of living cells, 
accumulate within the nucleous. If the target is in the 
nucleus this will be beneficial and the biological properties 
of antigene oligonucleotides and aptamer compounds will 
be improved. However, as some mRNAs are localized in 
the cell RNA targeting drugs such as ribozymes should 






After a long period of ups and downs, antisense 
technologies have gained increasing attention in recent 
years. Advances in recombinant DNA technology and 
synthetic chemistry have led to novel nucleic acid drugs 
that inhibit gene expression and protein function as 
evidenced by various studies. Major improvements have 
been achieved by the development of modified nucleotides 
that provide high target affinity, enhanced biostability and 
low toxicity. By developing a suitable drug delivery system, 
these drugs can emerge as novel therapeutics in the area 
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